Handen Benjamin L, Mapstone Mark, Hartley Sigan, Andrews Howard, Christian Brad, Lee Joseph H, Tudorascu Dana, Hom Christy, Ances Beau M, Zaman Shahid, Krinsky-McHale Sharon, Brickman Adam M, Rosas H Diana, Cohen Annie, Petersen Melissa, O'Bryant Sid, Harp Jordan P, Schmitt Frederick, Ptomey Lauren, Burns Jeffrey, Lott Ira T, Lai Florence, Silverman Wayne, Laymon Charles, Head Elizabeth
University of Pittsburgh, Department of Psychiatry, Pittsburgh, Pennsylvania, USA.
University of California, Irvine, Department of Neurology, Irvine, California, USA.
Alzheimers Dement. 2025 May;21(5):e70294. doi: 10.1002/alz.70294.
Virtually all adults with Down syndrome (DS) will accumulate the neuropathologies associated with Alzheimer's disease (AD) by age 40, with the majority having a clinical dementia diagnosis by their middle 50s.
This paper complements a 2020 publication describing the Alzheimer's Biomarker Consortium-Down Syndrome (ABC-DS) methodology by highlighting protocol changes since initial funding in 2015. It describes available clinical, neuropsychological, neuroimaging, and biofluid data and bio-specimen repository. Ten years of accomplishments are summarized.
Over 500 adults with DS and 59 sibling controls have been enrolled since 2015 with nearly 800 follow-up visits. More than 900 magnetic resonance imaging (MRI), 800 amyloid positron emission tomography (PET), and 600 tau PET scans have been conducted; multiple omics data have been generated using over 1100 blood and 100 cerebrospinal fluid (CSF) samples.
ABC-DS is the largest U.S.-based, multi-site (including the United Kingdom and Puerto Rico), longitudinal biomarker initiative to target adults with DS at risk for AD.
The Alzheimer's Biomarker Consortium-Down Syndrome (ABC-DS) is entering its 10th year. Over 500 adults with Down syndrome (DS) and 59 sibling controls have been enrolled. More than 900 magnetic resonance imaging (MRI), 800 amyloid positron emission tomography (PET), and 600 tau PET scans have been conducted. Multiple omics data have been generated using over 1100 blood and 100 cerebrospinal fluid (CSF) samples. It is positioned to continue to make substantial contributions to the DS field.
几乎所有成年唐氏综合征（DS）患者在40岁时都会出现与阿尔茨海默病（AD）相关的神经病理学变化，大多数人在55岁左右会被临床诊断为痴呆。
本文通过强调自2015年初始资助以来的方案变化，对2020年发表的描述阿尔茨海默病生物标志物联盟-唐氏综合征（ABC-DS）方法的文章进行补充。它描述了可用的临床、神经心理学、神经影像学和生物流体数据以及生物样本库。总结了十年的成果。
自2015年以来，已招募了500多名成年DS患者和59名同胞对照，进行了近800次随访。已进行了900多次磁共振成像（MRI）、800次淀粉样蛋白正电子发射断层扫描（PET）和600次tau PET扫描；使用超过1100份血液和100份脑脊液（CSF）样本生成了多组学数据。
ABC-DS是美国最大的多中心（包括英国和波多黎各）纵向生物标志物研究项目，旨在针对有AD风险的成年DS患者。
阿尔茨海默病生物标志物联盟-唐氏综合征（ABC-DS）已进入第10个年头。已招募了500多名成年唐氏综合征（DS）患者和59名同胞对照。已进行了900多次磁共振成像（MRI）、800次淀粉样蛋白正电子发射断层扫描（PET）和600次tau PET扫描。使用超过1100份血液和100份脑脊液（CSF）样本生成了多组学数据。它有望继续为DS领域做出重大贡献。
Zotero 插件